Researchers identified three new all-oral drug regimens that include at least one of two new drugs for treatment of rifampin-resistant tuberculosis, according to a study. The study tested five all ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI trials in mHSPC.

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and ...

The platform trial is examining different regimens and therapeutic options for the condition that the US Centres for Disease Control (CDC) affected more than 30,000 people in 2018 alone.

However, the panel notes that "For those who are not eligible for these shorter regimens, the 2016 and 2019 recommendations should be consulted." Using the thorough, evidence-based Grading of ...

This systematic review aimed to quantify maternal adverse effects attributed to treatment, assess how adverse effects vary according to different regimens, and explore women's experiences with ...